Get the latest news, insights, and market updates on ATAI (Atai Life Sciences N.V.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
AtaiBeckley Completes Redomiciliation to the United States
NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of t Dec 31, 2025 - $ATAI
JonesTrading Highlights Differentiated Pipeline at Atai Beckley N.V. (ATAI)
Atai Beckley N.V. (NASDAQ:ATAI) is among the Best Get Rich Fast Stocks to Buy Right Now. On December 23, Justin Walsh from JonesTrading initiated coverage on Atai Beckley N.V. (NASDAQ:ATAI) with a ‘Buy’ rating and a price target of $16, according to TheFly. This translates to an upside potential of nearly 282%. According to the […] Dec 27, 2025 - $ATAI
Atai Life Sciences (ATAI): Assessing an Expensive-Looking Valuation After a Strong Share Price Run
Atai Beckley (ATAI) has quietly become one of the more talked about mental health biotech names this year, with the stock swinging sharply even as its late stage psychedelic pipeline moves through key Phase 2 readouts. See our latest analysis for Atai Beckley. The latest pullback has not undone what has been a powerful run, with Atai Beckley posting a year to date share price return of 161.88 percent and a 1 year total shareholder return of 240.65 percent. This suggests momentum is still very... Dec 25, 2025 - $ATAI
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. “2025 has been a defining year for AtaiBeckley, marked b Dec 23, 2025 - $ATAI
MarketBeat’s Top 5 Rated Small-Cap Stocks
Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment. Dec 22, 2025 - $ATAI
Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation
Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy right now. ATAI Life Sciences holds a Strong Buy consensus from 8 analysts, with a 12‑month average target of $12.71 (range $10–$16), implying a 204% upside from the current $4.18. On December 11, the United States Patent and Trademark Office […] Dec 18, 2025 - $ATAI
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Cronos Acquired Europe’s Largest Adult-use Cannabis Company Aurora Introduced a New Proprietary Cultivar to Polish Market Trulieve Redeemed Costly 2026 Senior Secured Notes and Lined Up Fresh $100M Financing Key Takeaways; Psychedelic Sector Enveric Strengthened Mental Health Drug Pipeline with a New Patent Milestone PharmAla Marked Key Manufacturing Milestone with Australian-Made […] Dec 15, 2025 - $ATAI
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term exclusiv Dec 11, 2025 - $ATAI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple